Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CP-675, 206 · 1 trial · 1 indication
A 6-month progression free survivor will be defined as a patient who is alive and who has not progressed at 6 months or more post treatment.
| Arm | Type | Description |
|---|---|---|
| Open Label CP-675,206 | EXPERIMENTAL | Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of every 90-day cycle for up to 4 cycles or until disease progression or intolerance of toxicity. |
| Name | Type | Description |
|---|---|---|
| CP-675,206 | DRUG | Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of ever 90 cycle for up to 4 cycles or until progression or intolerance of toxicity. Tumor assessments will be done ever 3 months. Additional scans will be done if clinically indicated. |
Inclusion Criteria: * Histologically confirmed uveal melanoma including choroidal melanoma, iris melanoma, and ciliary body melanoma * Patients may either have measurable disease or non-measurable disease. * Biopsies from a readily accessible site of disease on study enrollment are mandatory in pri...
CP-675,206 is an investigational small molecule being studied for the treatment of uveal melanoma, a type of eye cancer. It is currently in Phase 2 clinical development for this indication.
CP-675,206 targets CTLA-4, an immune checkpoint protein. By targeting CTLA-4, the drug is designed to modulate the immune system's response against cancer cells.
CP-675,206 is being developed by Avalon GloboCare Corp., a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with uveal melanoma.
CP-675,206 is in Phase 2 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities for commercial use.
CP-675,206 has been studied in a Phase 2 clinical trial with the identifier NCT01034787. This trial, titled 'Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma,' was conducted in Canada and enrolled 11 participants.
CP-675,206 is also known as tremelimumab. It is a fully human monoclonal antibody that targets CTLA-4 and is being investigated for the treatment of uveal melanoma.